Abstract:
:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as well as trisomy 8 and we have previously reported that hydroquinone (HQ) induces deletions of 5, 7 and 8. Benzene metabolism is a requirement for bone marrow toxicity and the phenolic metabolites, HQ and catechol (CAT), have been implicated in benzene hematotoxicity. A research project was designed to determine whether CAT by itself and in conjunction with HQ could directly induce loss of chromosome 5 and/or 7 and gain of chromosome 8. Using fluorescence in situ hybridization with chromosome-specific 5, 7, and 8 probes we demonstrate that 5 to 150 uM CAT does not produce chromosomal aberrations, however CAT and 25 uM HQ can act in synergy to induce dose dependent loss of these chromosomes. In addition HQ/CAT selectively induces -5q which is not observed for HQ only. These results demonstrate for the first time that CAT/HQ act in synergy to induce specific chromosome loss found in secondary MDS/AML.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Stillman WS,Varella-Garcia M,Irons RDdoi
10.3109/10428199909145730keywords:
subject
Has Abstractpub_date
1999-10-01 00:00:00pages
269-81issue
3-4eissn
1042-8194issn
1029-2403journal_volume
35pub_type
杂志文章abstract::Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309147353
更新日期:1993-05-01 00:00:00
abstract::Leukemia is a result of accumulating genetic alterations. The collaboration of mutations that offer survival and proliferative signals, together with mutations that result in lack of differentiation, is thought to cause a leukemic phenotype. The cyclic-AMP Response Element Binding Protein (CREB) is a transcription fac...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/1042819031000151095
更新日期:2004-02-01 00:00:00
abstract::Abstract Increasing manganese superoxide dismutase (MnSOD) expression can suppress the malignant phenotype in various cancer cell lines and suppress tumor formation in xenograft and transgenic mouse models. A mimic of manganese superoxide dismutase (MnSODm), synthesized by a chemical method, has been shown to possess ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.825904
更新日期:2014-05-01 00:00:00
abstract::Several clinical and cell biological features, such as sex, age, leukemic cell burden, morphologic FAB type, and immunophenotype, have prognostic value in childhood acute lymphoblastic leukemia (ALL). The explanation for their prognostic significance is unclear, but might be related to cellular drug resistance. We pro...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199509112198
更新日期:1995-11-01 00:00:00
abstract::We present a case of adult T-cell leukemia (ATL) with jejunal perforation at the site of intestinal involvement by ATL. A 39-year-old woman presented with sudden-onset abdominal pain. Physical examination showed generalized severe abdominal tenderness and intraabdominal free air was seen on radiographic examination. U...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190109097774
更新日期:2001-11-01 00:00:00
abstract::The induction of apoptosis following topoisomerase inhibitors proceeds in at least three distinct steps: (1) induction of cleavable complexes (potentially lethal damage), (2) topoisomerase-induced DNA damage, and (3) a presently unknown sequence of events that must either lead to cell cycle arrest (G2-block, different...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199409051674
更新日期:1994-09-01 00:00:00
abstract::The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ib...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2017.1315115
更新日期:2017-12-01 00:00:00
abstract::One hundred and seventy-five hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day 4th International Workshop on Positron Emission Tomography in Lymphoma held in October 2012. The meeting was under the auspices of the European Lymphoma Institute, the Lymphoma Study Association (LYSA) a...
journal_title:Leukemia & lymphoma
pub_type:
doi:10.3109/10428194.2013.802784
更新日期:2014-01-01 00:00:00
abstract::In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190290005964
更新日期:2002-02-01 00:00:00
abstract::Blastic Natural Killer (NK)-cell lymphoma is a relatively new entity which has been recently included in the WHO classification. CD4 expression is observed in most cases of blastic NK-cell lymphomas and has been related with skin tropism. We report an unusual CD4 negative blastic NK-cell lymphoma with primary presenta...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190410001723232
更新日期:2004-10-01 00:00:00
abstract::There is increasing evidence for an interaction between acute leukemia cells and the microenvironment of the bone marrow. Blast cells from cases of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) bind to cellular and extracellular matrix components of the bone marrow stroma. In AML, adhesion to str...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509064917
更新日期:1995-06-01 00:00:00
abstract::Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2019.1581934
更新日期:2019-10-01 00:00:00
abstract::Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and fatal disease of early childhood characterized by a non-malignant accumulation of activated T lymphocytes and histiocytes in the reticuloendothelial system. Moreover, immune system derangement, with prominent hypercytokinemia and low or absent cytotoxic T...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428190109097672
更新日期:2001-06-01 00:00:00
abstract::Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poo...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199409049697
更新日期:1994-08-01 00:00:00
abstract::The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1080/1042819031000063471
更新日期:2003-04-01 00:00:00
abstract::Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3109/10428199409049634
更新日期:1994-05-01 00:00:00
abstract::Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cel...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2018.1434886
更新日期:2018-11-01 00:00:00
abstract::We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428199909169627
更新日期:1999-11-01 00:00:00
abstract::FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190802709438
更新日期:2009-03-01 00:00:00
abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.3109/10428194.2011.627480
更新日期:2012-05-01 00:00:00
abstract::Castleman's disease is a rare condition characterized by benign hyperplastic lymph nodes. Based on the morphological features, it has been divided into hyaline-vascular, plasma cell and intermediate types. The latter two types are frequently associated with a wide variety of clinical pictures such as fever, anemia wit...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199009069289
更新日期:1990-01-01 00:00:00
abstract::The relative scarcity of Hodgkin (H) and Reed-Sternberg (RS) cells within biopsies from cases with Hodgkin's disease (HD) is an impediment to the analysis of the nature and function of these cells. Continuous cell lines as uniform and permanently available sources of cells provide a valid alternative. Development of H...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199309148499
更新日期:1993-01-01 00:00:00
abstract::The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.588761
更新日期:2011-10-01 00:00:00
abstract::Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009087034
更新日期:2000-07-01 00:00:00
abstract::Hodgkin lymphomas are characterised by the presence of rare malignant cells in a background of non-neoplastic inflammatory cells. Flow cytometric analysis of involved tissues is generally not thought to be useful in establishing the diagnosis, because of the small number of neoplastic cells present. However, two recen...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190802308728
更新日期:2008-10-01 00:00:00
abstract::Splenectomy specimens from 8 cases of chronic lymphocytic leukaemia (CLL) were examined. The infiltrate in the red pulp consisted predominantly of small lymphocytes. In contrast the predominant cells in the white pulp were pro-lymphocytes and para-immunoblasts. The Ki67 marker, which identifies cells in growth phase, ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428199009169601
更新日期:1990-01-01 00:00:00
abstract::Current understanding of molecular genetics enables the establishment of new categories based on pathogenesis. Philadelphia (Ph) chromosome-positive leukemia has been reclassified into two molecularly distinct subsets, and the leukemogenesis at the cell level might be linked to the molecular changes. Therefore, treatm...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199309148502
更新日期:1993-01-01 00:00:00
abstract::Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2010.546921
更新日期:2011-02-01 00:00:00
abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190701837330
更新日期:2008-03-01 00:00:00
abstract::Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199709042492
更新日期:1997-03-01 00:00:00